what-is-peptide-science The dominant search intent for "what is peptide sequence of peptide 1 of mage 1" is to identify specific peptide sequences associated with the MAGE-1 gene, particularly those recognized as antigens. The SERP results indicate a strong focus on MAGE-1's role as a tumor antigen and the presentation of its derived peptides to T cells.
Tier 1:
* Core Entities: MAGE-1, Peptide Sequence
* High-Relevance Phrases: MAGE-1 peptide, peptide recognized by human cytolytic T lymphocytes, tumor-specific antigenic peptide, MAGE-1 (161-169), MAGE-1 (102-112)
Tier 2:
* Supporting Entities: MAGE-A1, MAGE-A4, HLA-A2, HLA-DR15
* Attributes/Variations: 15-mer sequences, nonamerpeptide sequences, antigen presentation, cytotoxic T lymphocytes (CTLs)
* Specific Sequences: Glu-Ala-Asp-Pro-Thr-Gly-His-Ser-Tyr, ITKKVADLVGF, FLLLKYRAREPVTKAE, KVLEYVIKV, SESIKKKVL
Tier 3:
* General terms like "peptide," "sequence," "sequences," "1," "MAGE," "MAGED1," "peptide acetate," "PepTivator."
---
The MAGE-1 (Melanoma-Associated Antigen 1) gene encodes tumor-specific antigenic peptides that are recognized by the human immune system, particularly by cytotoxic T lymphocytes (CTLs). Understanding the specific peptide sequences derived from MAGE-1 is crucial for research into cancer immunotherapy and the development of targeted vaccines. While the MAGE-1 gene itself codes for a protein, it is the processed fragments, or peptides, that are presented on the cell surface and can elicit an immune response.
Research has identified several MAGE-1 derived peptides that are significant for their immunogenic properties作者：N ROCH·2010·被引用次数：16—MAGE-A1 was first reported to encode a tumour-specificpeptideantigen on melanoma cell line MZ2-MEL, which could be recognised by cytotoxic T lymphocytes (CTLs) .... These peptides are often characterized by the portion of the MAGE-1 protein they originate from, indicated by amino acid residue numbers.
One of the most frequently cited MAGE-1 peptide sequences is Glu-Ala-Asp-Pro-Thr-Gly-His-Ser-Tyr, often referred to as MAGE-1 (161-169). This nonamer peptide has been identified as an antigenic epitope. Another important sequence identified is ITKKVADLVGF, corresponding to the MAGE-1 (102-112) region. This peptide has also been shown to be recognized by cytolytic T lymphocytes.
Other identified MAGE-1 peptides include sequences like FLLLKYRAREPVTKAE and SESIKKKVL, which are also subjects of investigation for their potential role in anti-tumor immunity. The presentation of these peptides by Major Histocompatibility Complex (MHC) molecules, such as HLA-A2 and HLA-DR15, is a critical step in initiating an immune response against cancer cells expressing MAGE-1The first step of peptide selection in antigen presentation by MHC class ....
The MAGE family of genes, including MAGE-1, are considered cancer-testis antigens (CTAs). They are typically expressed in germ cells but are aberrantly re-expressed in various types of cancer, making them attractive targets for cancer immunotherapy. The ability of MAGE-1 peptides to be presented by HLA molecules and recognized by T cells forms the basis for developing therapeutic strategies like peptide-based vaccines. These vaccines aim to stimulate the patient's own immune system to target and eliminate cancer cells expressing MAGE-1 antigensMAGE-1 Antigen (161-169), human; CAS 144449-86-5.
Research continues to explore various MAGE-1 derived peptides and their specific binding affinities to different HLA types, seeking to optimize peptide selection for maximum immunogenic potential and therapeutic efficacy.Coexpression of MAGE-A Peptides and HLA Class I ... For instance, some studies focus on identifying MAGE-1 peptides that can be presented by HLA-A1 or HLA-C molecules, further expanding the potential applications in personalized cancer treatment.
The peptide sequences of MAGE-1, such as MAGE-1 (161-169) with the sequence Glu-Ala-Asp-Pro-Thr-Gly-His-Ser-Tyr and MAGE-1 (102-112) with the sequence ITKKVADLVGF, are critical components in understanding the immune response against MAGE-1 expressing tumors. Their identification and characterization are fundamental for advancing cancer immunotherapy research, with the ultimate goal of developing effective treatments that harness the power of the immune system to combat cancer.
Join the newsletter to receive news, updates, new products and freebies in your inbox.